In a significant move within the pharmaceutical industry, Krka, a leading international generic pharmaceutical company based in Novo Mesto, Slovenia, and Laurus Labs (“Laurus” or “the Company”), have announced the formation of a joint venture (JV) company, Krka Pharma Pvt. Ltd., in Hyderabad, India. The venture marks a new chapter in the longstanding relationship between […]
Laurus Labs Ltd., a prominent pharmaceutical and biotech R&D entity in India, has released its H1 FY24 financial results. The firm reported a revenue of ₹ 2,406 Cr and an EBITDA of ₹ 356 Cr. Q2 FY24 Financial Overview For Q2 FY24, Laurus Labs showcased: Revenue of ₹ 1,224 crs, witnessing a decrease of 22% […]
Hyderabad-based pharmaceutical company Laurus Labs has announced a significant investment in Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy firm. The deal, valued at INR 80 crores, will increase Laurus Labs’ stake in ImmunoACT to 33.86% on a fully diluted basis. This strategic move is expected to provide ImmunoACT with the necessary capital […]
Laurus Labs said that it has acquired a stake of 26.62% in Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an Indian cell and gene therapy company for a sum of around INR 46 crores in cash. Apart from that, ImmunoACT will also get an investment of INR 9.75 crores from its senior management for a stake […]
Rising Pharmaceuticals has launched a generic version of Lyrica, (pregabalin) Capsules in the US, in all eight commercially available strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. According to IMS Health, Pregabalin Capsules had sales of around $5.5bn in the US for the 12 […]